Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SAGE Therapeutics Inc SAGE

Healthcare Biotechnology
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of... see more

Recent & Breaking News (NDAQ:SAGE)

Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019

Business Wire December 27, 2018

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire December 5, 2018

Sage Therapeutics to Present at Piper Jaffray 30th Annual Healthcare Conference

Business Wire November 21, 2018

Sage Therapeutics Receives Notification of PDUFA Extension for ZULRESSO™ (brexanolone) Injection

Business Wire November 20, 2018

Sage Therapeutics to Present at Stifel 2018 Healthcare Conference

Business Wire November 7, 2018

Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress

Business Wire November 6, 2018

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire November 5, 2018

Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression

Business Wire November 2, 2018

Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss ZULRESSO™ (brexanolone) Injection for the Treatment of Postpartum Depression

Business Wire November 2, 2018

Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

Benzinga.com  November 1, 2018

Sage Therapeutics to Report Third Quarter 2018 Financial Results on Tuesday, November 6, 2018

Business Wire October 23, 2018

Detailed Research: Economic Perspectives on W.W. Grainger, Jabil, Grand Canyon Education, Sage Therapeutics, H. B. Fuller, and Jazz Pharmaceuticals — What Drives Growth in Today's Competitive Landscape

GlobeNewswire October 19, 2018

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire October 3, 2018

Sage Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference

Business Wire September 6, 2018

Sage Therapeutics Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire September 6, 2018

Sage Therapeutics Announces The Lancet Publishes Integrated Data from Pivotal Trials for Brexanolone Injection in Postpartum Depression

Business Wire August 31, 2018

Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress

Business Wire August 7, 2018

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire August 3, 2018

Sage Therapeutics to Present at Canaccord 38th Annual Growth Conference

Business Wire August 1, 2018

Sage Therapeutics to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

Business Wire July 24, 2018